Raphael Palacios, APRN
Psychiatric/Mental Health · Hollywood, FLNPI 1407462385
Payments from drug & device makers
Across 767 payments — averaging $21.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Johnson & Johnson$1K
- Vanda Pharmaceuticals Inc.$1K
- plus $7K from 26 others
What the payments were for
- Food & beverage$16,172100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 113 | $2,093 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 68 | $1,574 |
| Otsuka America Pharmaceutical, Inc. | 69 | $1,542 |
| Teva Pharmaceuticals USA, Inc. | 88 | $1,287 |
| Johnson & Johnson | 61 | $1,158 |
| Vanda Pharmaceuticals Inc. | 39 | $1,080 |
| Neurocrine Biosciences, Inc. | 34 | $1,065 |
| Axsome Therapeutics, Inc. | 30 | $843 |
| Indivior Inc. | 36 | $789 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $779 |
| Alkermes, Inc. | 36 | $695 |
| Almatica Pharma LLC | 35 | $669 |
| Corium, LLC | 25 | $604 |
| Bausch Health US, LLC | 21 | $371 |
| Sunovion Pharmaceuticals Inc. | 17 | $345 |
| Idorsia Pharmaceuticals US Inc | 14 | $304 |
| E.r. Squibb & Sons, L.L.C. | 5 | $219 |
| Lundbeck LLC | 9 | $199 |
| Braeburn Inc. | 7 | $149 |
| Ironshore Pharmaceuticals Inc. | 4 | $79 |
| Orexo US, Inc. | 4 | $77 |
| Supernus Pharmaceuticals, Inc. | 3 | $48 |
| Merck | 2 | $34 |
| Luye Pharma (USA) Ltd. | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Noven Therapeutics, LLC | 1 | $21 |
| Tris Pharma Inc | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Alfasigma USA, Inc. | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,178 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 14 | $114,309 |
| RexultiBrexpiprazole | 40 | $63,543 |
| VraylarCariprazine Hcl | 24 | $33,270 |
| Invega SustennaPaliperidone Palmitate | 12 | $26,362 |
| CaplytaLumateperone Tosylate | 12 | $19,149 |
| TrintellixVortioxetine Hydrobromide | 30 | $16,357 |
| Lurasidone Hcl | 44 | $9,016 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 97 | $6,034 |
| Aripiprazole | 45 | $3,644 |
| Duloxetine Hcl | 115 | $2,843 |
| Trazodone Hcl | 172 | $2,769 |
| Memantine Hcl | 47 | $2,335 |
| Mirtazapine | 122 | $2,016 |
| Bupropion XlBupropion Hcl | 87 | $1,865 |
| Quetiapine Fumarate | 133 | $1,680 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,065 | $114,30914 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,542 | $63,54340 claims |
| AbbVieVraylar | $2,093 | $33,27024 claims |
| Johnson & JohnsonInvega Sustenna | $1,158 | $26,36212 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,574 | $19,14912 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $779 | $16,35730 claims |
| Almatica Pharma LLCSertraline Hcl | $669 | $1,297161 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Hollywood
- Cindy DerequitoHollywood$18K
- Maria PimentelHollywood$18K
- Osner EtienneHollywood$16K
- Nafeeza AlliHollywood$15K
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Cheedy JajaTampa$266K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.